Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis

Masashi Bando, Hiroyoshi Yamauchi, Takashi Ogura, Hiroyuki Taniguchi, Kentaro Watanabe, Arata Azuma, Sakae Homma, Yukihiko Sugiyama, K. Chida, N. Keicho, Y. Nakanishi, N. Inase, M. Nishimura, Y. Inoue, H. Mukae, A. Yokoyama, Y. Taguchi, H. Takizawa, M. Mishima, Y. NishiokaY. Ishii, M. Munakata, N. Kohno, Hiroshima K. Kishi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic pulmonary fibrosis (IPF) in clinical practice. Methods This survey study was a retrospective observational study. A survey was used to collect clinical information on IPF cases that were treated with pirfenidone. This survey sheet came from physicians belonging to the Diffuse Lung Diseases Research Group. Results 502 patients at 22 institutes received pirfeidone treatment. Of the 502 cases, pirfenidone treatment was terminated in under one year in 186 cases (37.1%); adverse effect was the most frequent reason for termination. The pirfenidone treatment lasted for two years or longer in 111 cases (22.1%). The mean change in the forced vital capacity (FVC) was-30±224 (SD) mL in the first year of treatment,-158±258 mL in the second year, and-201±367 mL in the third year. FVC improved by 10% or more in the first year in 10 (14.7%) of 68 cases, and showed a change of ±10% in 47 (69.1%) cases. It showed a change of ±10% in the second and third years in 61.7% and 62.5% of the patients, respectively. Conclusion The FVC improved in only a small percentage of patients who received pirfenidone treatment for a long period of time. However, a decrease in the FVC was prevented for three years in over half of the cases.

Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalInternal Medicine
Volume55
Issue number5
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Idiopathic Pulmonary Fibrosis
Vital Capacity
Therapeutics
Lung Diseases
Observational Studies
pirfenidone
Retrospective Studies
Physicians
Safety
Research
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Bando, M., Yamauchi, H., Ogura, T., Taniguchi, H., Watanabe, K., Azuma, A., ... Kishi, H. K. (2016). Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. Internal Medicine, 55(5), 443-448. https://doi.org/10.2169/internalmedicine.55.5272

Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. / Bando, Masashi; Yamauchi, Hiroyoshi; Ogura, Takashi; Taniguchi, Hiroyuki; Watanabe, Kentaro; Azuma, Arata; Homma, Sakae; Sugiyama, Yukihiko; Chida, K.; Keicho, N.; Nakanishi, Y.; Inase, N.; Nishimura, M.; Inoue, Y.; Mukae, H.; Yokoyama, A.; Taguchi, Y.; Takizawa, H.; Mishima, M.; Nishioka, Y.; Ishii, Y.; Munakata, M.; Kohno, N.; Kishi, Hiroshima K.

In: Internal Medicine, Vol. 55, No. 5, 01.03.2016, p. 443-448.

Research output: Contribution to journalArticle

Bando, M, Yamauchi, H, Ogura, T, Taniguchi, H, Watanabe, K, Azuma, A, Homma, S, Sugiyama, Y, Chida, K, Keicho, N, Nakanishi, Y, Inase, N, Nishimura, M, Inoue, Y, Mukae, H, Yokoyama, A, Taguchi, Y, Takizawa, H, Mishima, M, Nishioka, Y, Ishii, Y, Munakata, M, Kohno, N & Kishi, HK 2016, 'Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis', Internal Medicine, vol. 55, no. 5, pp. 443-448. https://doi.org/10.2169/internalmedicine.55.5272
Bando, Masashi ; Yamauchi, Hiroyoshi ; Ogura, Takashi ; Taniguchi, Hiroyuki ; Watanabe, Kentaro ; Azuma, Arata ; Homma, Sakae ; Sugiyama, Yukihiko ; Chida, K. ; Keicho, N. ; Nakanishi, Y. ; Inase, N. ; Nishimura, M. ; Inoue, Y. ; Mukae, H. ; Yokoyama, A. ; Taguchi, Y. ; Takizawa, H. ; Mishima, M. ; Nishioka, Y. ; Ishii, Y. ; Munakata, M. ; Kohno, N. ; Kishi, Hiroshima K. / Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. In: Internal Medicine. 2016 ; Vol. 55, No. 5. pp. 443-448.
@article{06a9303179e04bf8a55b44fd3694df76,
title = "Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis",
abstract = "Objective Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic pulmonary fibrosis (IPF) in clinical practice. Methods This survey study was a retrospective observational study. A survey was used to collect clinical information on IPF cases that were treated with pirfenidone. This survey sheet came from physicians belonging to the Diffuse Lung Diseases Research Group. Results 502 patients at 22 institutes received pirfeidone treatment. Of the 502 cases, pirfenidone treatment was terminated in under one year in 186 cases (37.1{\%}); adverse effect was the most frequent reason for termination. The pirfenidone treatment lasted for two years or longer in 111 cases (22.1{\%}). The mean change in the forced vital capacity (FVC) was-30±224 (SD) mL in the first year of treatment,-158±258 mL in the second year, and-201±367 mL in the third year. FVC improved by 10{\%} or more in the first year in 10 (14.7{\%}) of 68 cases, and showed a change of ±10{\%} in 47 (69.1{\%}) cases. It showed a change of ±10{\%} in the second and third years in 61.7{\%} and 62.5{\%} of the patients, respectively. Conclusion The FVC improved in only a small percentage of patients who received pirfenidone treatment for a long period of time. However, a decrease in the FVC was prevented for three years in over half of the cases.",
author = "Masashi Bando and Hiroyoshi Yamauchi and Takashi Ogura and Hiroyuki Taniguchi and Kentaro Watanabe and Arata Azuma and Sakae Homma and Yukihiko Sugiyama and K. Chida and N. Keicho and Y. Nakanishi and N. Inase and M. Nishimura and Y. Inoue and H. Mukae and A. Yokoyama and Y. Taguchi and H. Takizawa and M. Mishima and Y. Nishioka and Y. Ishii and M. Munakata and N. Kohno and Kishi, {Hiroshima K.}",
year = "2016",
month = "3",
day = "1",
doi = "10.2169/internalmedicine.55.5272",
language = "English",
volume = "55",
pages = "443--448",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "5",

}

TY - JOUR

T1 - Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis

AU - Bando, Masashi

AU - Yamauchi, Hiroyoshi

AU - Ogura, Takashi

AU - Taniguchi, Hiroyuki

AU - Watanabe, Kentaro

AU - Azuma, Arata

AU - Homma, Sakae

AU - Sugiyama, Yukihiko

AU - Chida, K.

AU - Keicho, N.

AU - Nakanishi, Y.

AU - Inase, N.

AU - Nishimura, M.

AU - Inoue, Y.

AU - Mukae, H.

AU - Yokoyama, A.

AU - Taguchi, Y.

AU - Takizawa, H.

AU - Mishima, M.

AU - Nishioka, Y.

AU - Ishii, Y.

AU - Munakata, M.

AU - Kohno, N.

AU - Kishi, Hiroshima K.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic pulmonary fibrosis (IPF) in clinical practice. Methods This survey study was a retrospective observational study. A survey was used to collect clinical information on IPF cases that were treated with pirfenidone. This survey sheet came from physicians belonging to the Diffuse Lung Diseases Research Group. Results 502 patients at 22 institutes received pirfeidone treatment. Of the 502 cases, pirfenidone treatment was terminated in under one year in 186 cases (37.1%); adverse effect was the most frequent reason for termination. The pirfenidone treatment lasted for two years or longer in 111 cases (22.1%). The mean change in the forced vital capacity (FVC) was-30±224 (SD) mL in the first year of treatment,-158±258 mL in the second year, and-201±367 mL in the third year. FVC improved by 10% or more in the first year in 10 (14.7%) of 68 cases, and showed a change of ±10% in 47 (69.1%) cases. It showed a change of ±10% in the second and third years in 61.7% and 62.5% of the patients, respectively. Conclusion The FVC improved in only a small percentage of patients who received pirfenidone treatment for a long period of time. However, a decrease in the FVC was prevented for three years in over half of the cases.

AB - Objective Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic pulmonary fibrosis (IPF) in clinical practice. Methods This survey study was a retrospective observational study. A survey was used to collect clinical information on IPF cases that were treated with pirfenidone. This survey sheet came from physicians belonging to the Diffuse Lung Diseases Research Group. Results 502 patients at 22 institutes received pirfeidone treatment. Of the 502 cases, pirfenidone treatment was terminated in under one year in 186 cases (37.1%); adverse effect was the most frequent reason for termination. The pirfenidone treatment lasted for two years or longer in 111 cases (22.1%). The mean change in the forced vital capacity (FVC) was-30±224 (SD) mL in the first year of treatment,-158±258 mL in the second year, and-201±367 mL in the third year. FVC improved by 10% or more in the first year in 10 (14.7%) of 68 cases, and showed a change of ±10% in 47 (69.1%) cases. It showed a change of ±10% in the second and third years in 61.7% and 62.5% of the patients, respectively. Conclusion The FVC improved in only a small percentage of patients who received pirfenidone treatment for a long period of time. However, a decrease in the FVC was prevented for three years in over half of the cases.

UR - http://www.scopus.com/inward/record.url?scp=84959263791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959263791&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.55.5272

DO - 10.2169/internalmedicine.55.5272

M3 - Article

C2 - 26935361

AN - SCOPUS:84959263791

VL - 55

SP - 443

EP - 448

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 5

ER -